| |
|
今井 浩三 |
東京大学医科学研究所・特任教授 |
| 分子腫瘍学、臨床腫瘍学 |
| Mesenchymal stem cells cancel azoxymethane-induced tumor initiation. Nasuno M, Arimura Y, Nagaishi K, Isshiki H, Onodera K, Nakagaki S, Watanabe S, Idogawa M, Yamashita K, Naishiro Y, Adachi Y, Suzuki H, Fujimiya M, Imai K, Shinomura Y. Stem Cells 2014.32(4):913-925, doi: 10.1002/stem.1594. |
| Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, Nishida T, Bamba T, Kanda T, Ajioka Y, Taguchi T, Okahara S, Takahashi H, Nishida Y, Hosokawa M, Hasegawa T, Tokino T, Hirata K, Imai K, Toyota M, Shinomura Y. Cancer Res. 2012; 72(5):1126-1136. |
| Genome-wide profiling of chromatin signatures reveals epigenetic regulation of microRNA genes in colorectal cancer. Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R, Kai M, Yamano HO, Sasaki Y, Tokino T, Shinomura Y, Imai K, Toyota M. Cancer Res. 2011; 71: 5646-5658. |
|
| |
|
上西 紀夫 |
公立昭和病院企業団企業長兼院長 |
| 消化器外科、消化器内視鏡、消化器癌発生 |
| Kaminishi M, Shimizu N, Shimoyama S, Yamaguchi H, Hashimoto M, Ogawa T, Sakai S, Oohara T. Different carcinogenesis in the gastric remnant following gastrectomy for gastric cancer. Cancer 77:1646-1653, 1996 |
| Shimuzu N, Ikehara Y, Inada K, Nakanishi H, Tsukamoto T, Nozaki K, Kaminishi M, Kuramoto S, Sugiyama A, Katsuyama T, Tatematsu M. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian Gerbils. Cancer Res 60:1512-1514,2000 |
“The Diversity of Gastric Carcinoma” Kaminishi M et al. (eds),
Springer, 2005
|
|
| ○ |
|
江口 研二 |
帝京大学医学部 難治疾患支援学講座 特任教授 |
| 腫瘍内科学 緩和医療学 |
H Kinoshita, I Maeda, T Morita, M Miyashita, A Yamagishi, Y Shirahige, T Takebayashi, T Yamaguchi, A Igarashi, K Eguchi.
Place of Death and the Differences in Patient Quality of Death and Dying and Caregiver Burden. J Clin Oncol 33; 4: 357-63, 2015
|
| N. Katakami, H. Kunikane, K. Takeda, K. Takayama, T. Sawa, H. Saito, M. Harada, S. Yokota, K. Ando, Y. Saito, I Yokota, Y. Ohashi, K Eguchi. Prospective Study on the Incidence of Bone Metastasis (BM) and Skeletal-Related Events (SREs) in Patients (pts) with Stage IIIB and IV Lung Cancer-CSP-HOR13. J Thorac Oncol 9;(2): 231-8, 2014 |
| Matsuyama M, Ishii H, Furuse J, Ohkawa S, Maguchi H, Mizuno N, Yamaguchi T, Ioka T, Ajiki T, Ikeda M, Hakamada K, Yamamoto M, Yamaue H, Eguchi K, Ichikawa W, Miyazaki M, Ohhashi Y, Sasaki Y, Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer. Investigational New Drugs. 10.1007/s10637-014-0197-z (December) 2014 |
|
| |
|
小菅 智男 |
国立がん研究センター中央病院・副院長 |
| 外科学 |
| An isolated, complete resection of the caudate lobe, including the paracaval portion, for hepatocellular carcinoma. Tomoo Kosuge, Junji Yamamoto, Tadatoshi Takayama, Kazuaki Shimada, Susumu Yamasaki, Masatoshi Makuuchi, Hiroshi Hasegawa. Arch Surg.129:280-284,1994. |
| Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Tomoo Kosuge, Junji Yamamoto, Kazuaki Shimada, Susumu Yamasaki, Masatoshi Makuuchi. Ann Surg.230(5):663-671,1999. |
| A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Kosuge T, Kiuchi T, Mukai K, Kakizoe T. Jpn J Clin Oncol 36:159-165, 2006. |
|
| |
|
佐々木 康綱 |
昭和大学医学部・腫瘍内科学教授 |
| 癌薬物療法 |
| Yasutsuna Sasaki, Tomohiro Nishina, Hirofumi Yasui, Masahiro Goto, Kei Muro, Akihito Tsuji, Wasaburo Koizumi, Yasushi Toh, Hara Takuo and Yoshinori Miyata. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci (2014) 105:812-817 |
| Toshikado Kaneta, Ken-ichi Fujita, Yuko Akiyama, Kaori Kawara, Yu Sunakawa, Asuka Kawachi, Ken Shimada, Yasutsuna Sasaki, No pharmacokinetic alteration of docetaxel by coadministration of aprepitant 3 h before docetaxel infusion. Cancer Chemother Pharmacol (2014) 74:539-547 |
Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Hideo Baba, Masato Nakamura, Kazuhiro Yoshida, Motoki Yoshida,, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, Kenichi Sugihara. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomized phase 3 trial. Lancet Oncology (2014) 14:1278-86
|
|
| |
|
田村 和夫 |
福岡大学医学部腫瘍・血液・感染症内科学 教授 |
| 内科学、臨床腫瘍学、血液学 |
Prospective randomized study of cefepime, panipenem, or meropenem
monotherapy for patients with hematological disorders and febrile
neutropenia. Nakagawa Y, Suzuki K, Ohta K, Hino M, Ohyashiki K,
Kanamaru A, Tamura K, Urabe A, Masaoka T, the Japan Febrile Neutropenia
Study Group J Infect Chemother 19:103-111, 2013
|
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy
for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Takamatsu Y, Sunami K, Muta T, Morimoto H, Miyamoto T, Higuchi M,
Uozumi K, Hata H, Tamura K; Kyushu Hematology Organization for
Treatment Study Group (K-HOT). Int J Hematol 98(2):179-85, 2013
|
Empirical voriconazole therapy for febrile neutropenic patients with
hematological disorders: a prospective multicenter trial in Japan. Koh H,
Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N,
Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A,
Masaoka T. J Infect Chemother. 19(6):1126-34, 2013
|
|
| |
|
土屋 了介 |
地方独立行政法人神奈川県立病院機構 理事長 |
| |
| 平成22年4月より管理職専従のため、研究業績なし |
|
| |
|
早川 和重 |
北里大学医学部・主任教授 |
| 放射線腫瘍学 |
| A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds versus loose seeds for prostate brachytherapy. Ishiyama H, Satoh T, Kawakami S, Tsumura H, Komori S, Tabata K, Sekiguchi A, Takahashi R, Soda I, Takenaka K, Iwamura M, Hayakawa K. Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):134-9. |
| Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy? Soda I, Ishiyama H, Ono S, Takenaka K, Arai M, Arai T, Iwase H, Sekiguchi A, Kawakami S, Komori S, Onda T, Hayakawa K. J Radiat Res. 2015 Mar;56(2):354-9. |
| Definitive Chemoradiation Therapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-R) in Advanced Esophageal Cancer: A Phase 2 Trial (KDOG 0501-P2). Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, Koizumi W; Kitasato Digestive Disease and Oncology Group. Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):872-9. |
|
